CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
SYN-010drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02493036
NCT02493036Phase 2Completed
CompareCT.gov

A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation

Theriva Biologics, Inc.·interventional·Posted Jul 9, 2015·Updated Nov 27, 2018

In Brief

A Phase 2 clinical trial evaluating SYN-010 for Irritable Bowel Syndrome With Constipation (IBS-C). Completed, enrolled 54 participants across 11 sites.

Detailed Summary

A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome With Constipation (IBS-C)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 9, 2015
Enrollment StartOct 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.0 years ago

Interventions

SYN-010drug